Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 8/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 8/20 | 0.42 |
| ▸ | PARP1 | P09874 | 7/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160577 | 0.88 | PARP1 (0.47) | TNKSTNKS2PARP1HCAR2PARP2 | |
| SCHEMBL162385 | 0.88 | PARP1 (0.46) | TNKSTNKS2PARP1HCAR2PARP2 | |
| SCHEMBL162259 | 0.88 | TNKS (0.53) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL160963 | 0.88 | HCAR2 (0.37) | TNKSTNKS2PARP1HCAR2PARP2 | |
| SCHEMBL159396 | 0.82 | TNKS (0.39) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL161422 | 0.72 | GRM5 (0.34) | GRM5 | |
| SCHEMBL162154 | 0.71 | TUBB4A (0.43) | TNKSTNKS2PARP1PKMKDM5A | |
| SCHEMBL174265 | 0.67 | XPO1 (0.37) | — | |
| SCHEMBL526074 | 0.67 | PARP1 (0.70) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL577862 | 0.67 | PARP1 (0.51) | TNKSTNKS2PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633207-B2 | Quinazoline compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2611789-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030948-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053174-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, TYK2 | TNKS 225/4885TNKS2 166/4885PARP1 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.